^
Association details:
| Biomarker: | AREG overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel
Published date:
05/06/2020
Excerpt:
mCRC patients from the second-line PICCOLO trial of irinotecan versus irinotecan/panitumumab. PTL was classified as right-PTL, left-PTL or rectal-PTL…Patients with right-PTL and high EREG/AREG or HER3 expression, had IrPan PFS improvement (high EREG/AREG HR=0.20, p=0.04; high HER3 HR=0.33, p=0.10) compared with irinotecan. Similar effect was seen for rectal-PTL patients (high EREG/AREG HR=0.44, p=0.03; high HER3 HR=0.34, p=0.05).
Secondary therapy:
irinotecan
DOI:
10.1016/j.annonc.2020.04.476
Trial ID:
Source:
Title:
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
Excerpt:
EREG tumoural mRNA expression was significantly associated with a 2.26-fold increased likelihood of objective response to cetuximab therapy (RECIST 1.1). In multivariate analysis, favourable predictive factors were high AREG mRNA in KRAS wild type tumours, high EREG mRNA, low Ephrin A2 receptor mRNA.
DOI:
10.1186/1471-2407-13-49
Source:
Title:
Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer
Excerpt:
Combining HER3 and ligand data, patients with HER3-high, AREG/EREG-high tumors gained markedly from panitumumab (PFS HR, 0.24; 95% CI, 0.11-0.51; P < .005 and OS HR, 0.36; 95% CI, 0.18-0.73; P = .004). Conversely, patients with HER3-low, AREG/EREG-low tumors did not benefit (PFS HR, 1.14; 95% CI, 0.73-1.79; P = .57 and OS HR, 1.44; 95% CI, 0.92-2.26; P = .11).
Secondary therapy:
irinotecan
DOI:
10.1001/jamaoncol.2017.3168.
Trial ID:
